VNDA and ANAB Related Headlines

Go Back

Feb 25, 2026 07:19AM FDA accepts Vanda's drug application for rare skin disorder treatment

Feb 25, 2026 07:18AM Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

Dec 15, 2025 07:01AM Vanda submits FDA application for rare skin disorder drug

Dec 15, 2025 07:00AM Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

VNDA and ANAB Related Press Releases

Go Back

Feb 25, 2026 07:18AM Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

Dec 15, 2025 07:00AM Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

VNDA and ANAB Related SEC Filings

Go Back